泰达生物（08189）8月14日公告，公司董事会将于2026年8月31日10时在中国天津市天津经济技术开发区第四大街80号天大科技园A2座第9层召开董事会会议。会议将审阅并批准公司及其附属公司截至2026年6月30日止半年度未经审计的综合财务报表，并审议以下议程：\n\n1. 审批在香港联合交易所有限公司GEM网站刊载的2026年上半年业绩草拟公告；\n\n2. 考虑派付中期股息（如有）；\n\n3. 考虑暂停办理股份过户登记手续（如需要）；\n\n4. 考虑并批准其他事项（如有）。\n\n公告显示，泰达生物现任董事会成员包括执行董事孙莉女士、杨增先生；非执行董事何昕先生、李锡明博士、王磊先生、夏瑞哲先生；独立非执行董事高纯女士、涂相珍先生及陈江先生。\n\n根据GEM上市规则，本公告自刊发日期起至少连续七日于GEM网站及公司官网公开披露。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.